Johnny Mahlangu on Muck Rack

Johnny Mahlangu

Johannesburg
As seen in: Color Research & Application, Wiley Online Library, Journal of Clinical Pathology, The New England Journal of Medicine, The Lancet, Dove Medical Press, HemOnc Today, HAL, Future Medicine, EMJ- European Medical Journal
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Johnny

Contact Johnny, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Guidelines for management of hemophila why what and how

|
By Referenced By, A B Srivastava, Johnny Mahlangu
| wits.ac.za
Guidelines for management of hemophila why what and how
Open in Who Shared Issue with article?

Enhancing the Evidence for Care in Underserved Bleeding Disorders Communities

|
By Johnny Mahlangu, Haematology Faculty
| Wiley Online Library Verified
1 Introduction The evolution of bleeding disorder care represents one of medicine's most remarkable success stories. From the era when haemophilia was uniformly fatal in childhood to today's gene therapy trials promising functional cures, the trajectory of scientific progress has been extraordinary [1]. Yet this narrative of triumph obscures a troubling reality: the benefits of these advances remain profoundly inequitably distributed.
Open in Who Shared Issue with article?

Motivators and barriers affecting decisions to participate in sickle cell disease clinical trials in the global Learning and Insights into Sickle Cell Trial Experiences (LISTEN) Survey: global and regional findings

|
By Johnny Mahlangu, Raffaella Colombatti, John James
| The Lancet Verified
Get full text access Log in, subscribe or purchase for full access. References 1. Piel, FB ∙ Rees, DC ∙ DeBaun, MR ∙ et al. Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission Lancet Haematol. 2023; 10:e633-e686 2. Pfizer Pfizer voluntarily withdraws all lots of sickle cell disease treatment OXBRYTA (voxelotor) from worldwide markets. 2024 3.
Open in Who Shared Issue with article?
See all 27 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified